Sex differences in the developmental programming of cardiovascular and renal risk across the lifespan
Abstract
Cardiovascular (CV) disease remains the leading cause of death worldwide, with metabolic disorders nearly doubling CV risk mortality. Although adult lifestyle factors contribute to disease development, increasing evidence supports a critical role for developmental programming in shaping the long-term cardiac health. The developmental origins of health and disease concept, first proposed by Barker, associates low birth weight with increased CV risk in adulthood. Subsequent studies demonstrated that maternal health, including undernutrition, smoking, preeclampsia (PE), autoimmune diseases, and polyendocrine metabolic ovarian syndrome (PMOS), is associated with impaired fetal growth and increased susceptibility to CV, renal, and metabolic disease in offspring. Conversely, high birth weight, associated with maternal or parental obesity, is linked to elevated risk of obesity, type 2 diabetes, renal susceptibility, and heart failure later in life. Preclinical models of developmental insults identify key mechanistic pathways, including activation of the renin-angiotensin system, sympathetic nervous system, oxidative stress, and immune dysregulation, with additional sex-specific differences in susceptibility to adverse outcomes after injury. Despite advances, preventive strategies targeting the preconception and gestational periods remain limited. This review highlights mechanisms linking impaired fetal growth induced via developmental exposure to PE, PMOS, maternal obesity, and…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.